Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialKohei Shitara, Maria Di Bartolomeo, Mario Mandalà et al.|The Lancet|2018Cited by 1.3k
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with SorafenibFrancesco Caputo, Andrea Casadei‐Gardini, Vincenzo Dadduzio et al.|PLoS ONE|2020Cited by 47